title: Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium.
abstract: This study examined the potential usefulness of cultured human nasal epithelium as a model to investigate nasal absorption enhancement strategies for therapeutic peptides. The transport of leucine enkephalin (Leu-Enk) in the presence of bestatin and puromycin, respectively and various combinations of these protease inhibitors with absorption enhancers capable of inhibiting proteases or protecting peptides against protease degradation (glycocholate, dimethyl-beta-cyclodextrin (DM beta CD)) was studied. Epithelial membrane perturbation, protein leakage, bestatin/puromycin absorption and rebound aminopeptidase activity were used as toxicological end-points. The combination of puromycin with glycocholate or DM beta CD resulted in a higher absorption enhancement of Leu-Enk (9-14%) than when the absorption enhancers were combined with bestatin (1-3%) or when the inhibitors were used alone (2-4%). The higher absorption enhancement resulting from the combination of protease inhibitors with absorption enhancers caused a significant reduction of epithelial resistance and increased sodium fluorescein transport. Although only puromycin permeated the human nasal epithelium, both protease inhibitors induced a significant rebound aminopeptidase activity (25-61%), which can be associated with protein leakage (21-46%). This study highlighted (i) the potential usefulness of cultured human nasal epithelium as a model to study nasal absorption enhancement of therapeutic peptides; (ii) further studies using in vivo nasal models are required to ascertain whether the membrane perturbation and cytotoxicity observed with various combinations of the protease inhibitors and absorption enhancers really raise safety concerns.
authors.affiliation: Laboratorium voor Farmacotechnologie en Biofarmacie, K.U. Leuven, Campus Gasthuisberg O&N, Herestraat 49, B-3000 Leuven, Belgium.
authors.forename: Remigius Uchenna
authors.initials: RU
authors.lastname: Agu
authors.forename: Hoang
authors.initials: H
authors.lastname: Vu Dang
authors.forename: Mark
authors.initials: M
authors.lastname: Jorissen
authors.forename: Tom
authors.initials: T
authors.lastname: Willems
authors.forename: Renaat
authors.initials: R
authors.lastname: Kinget
authors.forename: Norbert
authors.initials: N
authors.lastname: Verbeke
mesh_terms: D000042:Absorption / Q000502:physiology; D000281:Administration, Intranasal; D001692:Biological Transport; D002478:Cells, Cultured; D004743:Enkephalin, Leucine / Q000378:metabolism; D006801:Humans; D009297:Nasal Mucosa / Q000166:cytology / Q000378:metabolism*; D010455:Peptides / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000493:pharmacokinetics
chemical_list: D010455:Peptides; D011480:Protease Inhibitors; D004743:Enkephalin, Leucine